Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute PainBusiness Wire • 07/19/21
Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis PatientsBusiness Wire • 06/28/21
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic FibrosisBusiness Wire • 06/25/21
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del MutationBusiness Wire • 06/18/21